Vercauteren, Marcel

Profile Picture
Email Address
Birth Date
Organizational Units
Organizational Unit
Abdominal and Paediatric Surgery
Antwerp Surgical Training, Anatomy and Research Centre (ASTARC) is a multidisciplinary research team that incorporates the fundamental, clinical and translational research activities of 11 research laboratories of the Faculty of Medicine and Health Sciences at the University of Antwerp.
Organizational Unit
Aim of the laboratory : diagnosis of Malignant Hyperthermia (MH) susceptibility by means of in vitro contracture testing according to the protocol of the European MH Group (; detection of associated structural myopathies; clinical counselling concerning MH-susceptibility; genetic counselling.
Organizational Unit
Organizational Unit
Organizational Unit
Job Title
Head of Anaesthesiology
Last Name
First Name

Search Results

Now showing 1 - 2 of 2
  • Publication
    ( 2018-05-17) Medicine and Health Sciences ; Abdominal and Paediatric Surgery ; Eens, Marcel ; Vercauteren, Marcel ; De Wael, Karolien ; Abdominal and Paediatric Surgery
  • Publication
    Dengue Human Infection Models Supporting Drug Development
    ( 2014-06-15) Plain text author ; Plain text author 2 ; Eens, Marcel ; Vercauteren, Marcel ; Simmons, Cameron
    Dengue is a arboviral infection that represents a major global health burden. There is an unmet need for effective dengue therapeutics to reduce symptoms, duration of illness and incidence of severe complications. Here, we consider the merits of a dengue human infection model (DHIM) for drug development. A DHIM could allow experimentally controlled studies of candidate therapeutics in preselected susceptible volunteers, potentially using smaller sample sizes than trials that recruited patients with dengue in an endemic country. In addition, the DHIM would assist the conduct of intensive pharmacokinetic and basic research investigations and aid in determining optimal drug dosage. Furthermore, a DHIM could help establish proof of concept that chemoprophylaxis against dengue is feasible. The key challenge in developing the DHIM for drug development is to ensure the model reliably replicates the typical clinical and laboratory features of naturally acquired, symptomatic dengue.